Phase 2 N=15 Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes
Primary: Overall Response Rate (ORR) — 12; 0; 0; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=61 Urticaria Facticia Treatment With Omalizumab (UFO)
Symptomatic Dermographism
Primary: Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo — -1.8; -2.0; -0.6 wheal…
Phase 4 N=102 Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)
Rhinitis, Allergic, Seasonal
Primary: Percentage of Participants Who Experienced at Least One Event of Local Swelling — 13.7; 21.6; 14.7 Percentage of Participants
Phase 2 N=49 Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases
Metastatic Cancer
Primary: Radiographic Response Assessed by Macdonald Criteria Every 2 Months — 3; 2; 4; 3 participants
N/A N=302 Adjusting to Chronic Conditions Using Education, Support, and Skills
Chronic Obstructive Pulmonary Disease · Heart Failure · Anxiety
Primary: Patient Health Questionnaire -9 (PHQ-9) — 10.35; 13.28; 10.32; 13.49 units on a scale
N/A N=106 Evaluation of HealinG of Polymer-Free Biomlimus A9-Coated Stent by Optical Coherence Tomography (EGO-BIOFREEDOM)
Coronary Disease
Primary: OCT Findings on Coverage (Degree of Endothelialisation/Coverage) From 1 to 9 Months. — 85.77; 86.95; 88.56; 96.79 percentage of strut coverage (D+E+F)
Phase 4 N=60 TAP Block With Liposomal Bupivacaine Versus Bupivacaine in Robotic Hysterectomy
Acute Pain
Primary: Post Operative Opioid Use — 24.9; 51.7 micrograms of fentanyl equivalents
Phase 2 N=28 Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS
Myelodysplastic Syndrome · MDS
Primary: Number of Participants With Erythroid Response — 5 participants
Phase 4 N=20 Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users
Epilepsy · Contraception
Primary: Percent of Participants That Experienced Clinically Meaningful Change in Lamotrigine Level — 0 percentage of participants
Phase 3 N=162 Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
Hypertriglyceridemia
Primary: Percent Change in Triglyceride for All Subjects — -28.1; -10.2 Percentage of change (%) — p=0.017
N/A N=197 Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial
Breast Feeding · Contraception
Primary: Number of Participants Who Continued to Breastfeed at 6 Months — 15; 14; 8; 9 participants
Phase 2 N=42 SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study
Hepatitis C
Primary: To Determine the Effects of Sho-saiko-to on Hepatic Injury in Patients With Chronic Hepatitis C Who Are Intolerant or Have a Specific Contraindication to…
N/A N=25 Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder
Transitional Cell Carcinoma of the Bladder
Primary: Feasibility — 8; 15 participants
Phase 2 N=78 Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)
Mild Cognitive Impairment
Primary: Change in Cognitive Performance — 0.8; 0.7; 1.2; 0.4 units on a scale — p=<0.0125
Phase 3 N=42 Vaporized Cannabis and Spinal Cord Injury Pain
Spinal Cord Injuries · Spinal Cord Diseases
Primary: Number of Participants Achieving a Reduction in Pain Intensity of 30% or More — 18; 26; 35 participants — p=<.05